Gate2Brain
Private Company
Funding information not available
Overview
Gate2Brain is a private, preclinical-stage biotech leveraging a proprietary platform of peptide shuttles to ferry diverse drug cargoes (small molecules, biologics, nanoparticles) across biological barriers. Its flagship asset, G2B-002, has received Orphan Drug Designation from both the EMA and FDA for pediatric solid tumors and is advancing toward Phase 1 trials. The company positions itself as a deep-tech player addressing significant unmet medical needs in neurology, oncology, and rare diseases through a transformative delivery technology.
Technology Platform
Proprietary platform of three families of peptide shuttles that can be conjugated to diverse drug cargoes (small molecules, peptides, proteins, antibodies, nanoparticles) to facilitate their delivery across biological barriers like the blood-brain, blood-retinal, skin, and tumor barriers.
Opportunities
Risk Factors
Competitive Landscape
Gate2Brain operates in the competitive drug delivery technology space, specifically targeting the blood-brain barrier. It faces competition from companies using alternative shuttle technologies (e.g., antibody-based, exosome, or nanoparticle platforms). Its focus on peptide shuttles and a clear therapeutic proof-of-concept in pediatric oncology are key differentiators.